Tirzepatide/Glycine/B12

• Decreases appetite and reduces cravings
• Promotes weight loss
• Lowers A1C levels (a marker of blood sugar control)
• Enhances insulin sensitivity¹
• Improves cardiometabolic health measures⁴

• The medication is not insulin.
• Dose adjustments should aim for the lowest appropriate dose to limit side effects and improve adherence.
• Side effects such as nausea, constipation, acid reflux, stomach pain, vomiting, diarrhea, and injection site reactions are common.

Store refrigerated

• Contraindicated in patients with a history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia Syndromes (MEN 2)
• Consult your healthcare provider if you have a history of pancreatitis, as the medication may increase risk
• Serious side effects may involve hypoglycemia, kidney issues, or allergic reactions^1,5
• Not suitable for individuals with type 1 diabetes or diabetic ketoacidosis
• Medication interactions may occur with those on insulin, oral diabetes medications, oral contraceptives, and blood thinners. Prescribers should be mindful of the impacts that delayed gastric emptying and reduced blood sugar can have with other medications.
• Gastric emptying may be delayed, requiring caution for procedures involving sedation or general anesthesia due to aspiration risk
• Use caution in those with a history of diabetic retinopathy⁵
• Avoid use during pregnancy and breastfeeding⁶

• Enhances glucose-dependent insulin secretion
• Suppresses glucagon secretion
• Supports weight loss
• Slows gastric emptying
• Improves insulin sensitivity^1,2
• Influences brain regions involved in appetite regulation, leading to reduced hunger and caloric intake
• Helps to decrease internal inflammation¹

Q: How long does it take to see results? 

A: Benefits like appetite reduction and weight loss may be observed within weeks, but individual responses vary.

Q: Can I use this with other medications? 

A: It can be used with other medications, but it should not be used with other GLP-1 medications. Always inform your healthcare provider about all medications you're taking to to address possible interactions.

Q: Why is it formulated with glycine and vitamin B12?

A: Cyanocobalamin (vitamin B12) and glycine are added to support side effect management and muscle preservation.

Q: What if I miss an injection? 

A: Contact your healthcare provider for guidance on missed doses.

IMPORTANT INFORMATION ABOUT COMPOUNDED MEDICATIONS

This medication has been compounded (custom-prepared) by a pharmacy. Compounded medications are specially prepared for individual patient needs based on a valid prescription and, as such, are not reviewed or approved by the U.S. Food and Drug Administration (FDA) for safety or efficacy. These statements have not been evaluated by the FDA.

This compounded preparation:

• Has not been approved by the FDA
• Has not undergone FDA review for safety, effectiveness, or quality
• Is prepared specifically for you based on your prescriber's order
• Individual outcomes may vary

Dosing is determined by the prescribing provider based on patient-specific factors. Always follow your healthcare provider's instructions. Compounded medications are not subject to FDA approval and lack the same safety and efficacy data as FDA-approved commercial medications. This medication should be prescribed and monitored by a licensed healthcare professional familiar with the condition being addressed and the specific applications of the medication.

1. Chavda VP, Ajabiya J, Teli D, Bojarska J, Apostolopoulos V. Tirzepatide, a New Era of Dual-Targeted Treatment for Diabetes and Obesity: A Mini-Review. Molecules. 2022 Jul 5;27(13):4315. doi: 10.3390/molecules27134315. Erratum in: Molecules. 2025 Mar 07;30(6):1190. doi: 10.3390/molecules30061190.

2. Tirzepatide. Lexi-Drugs. UpToDate Lexidrug. Wolters Kluwer Health, Inc. Accessed May 12, 2025. https://online.lexi.com/lco/action/doc/retrieve/docid /patch_f/7224042

3. Sardar MB, Nadeem ZA, Babar M. Tirzepatide: A novel cardiovascular protective agent in type 2 diabetes mellitus and obesity. Curr Probl Cardiol. 2024 May;49(5):102489. doi: 10.1016/j.cpcardiol.2024.102489. Epub 2024 Feb 28.

4. Sardar MB, Nadeem ZA, Babar M. Tirzepatide: A novel cardiovascular protective agent in type 2 diabetes mellitus and obesity. Curr Probl Cardiol. 2024 May;49(5):102489. doi: 10.1016/j.cpcardiol.2024.102489. Epub 2024 Feb 28.

5. Caruso, I., Di Gioia, L., Di Molfetta, S. et al. The real-world safety profile of tirzepatide: pharmacovigilance analysis of the FDA Adverse Event Reporting System (FAERS) database. J Endocrinol Invest 47, 2671–2678 (2024). https://doi.org/10.1007/s40618-024-02441-z

6. American College of Obstetricians and Gynecologists (ACOG). Obesity in pregnancy: ACOG practice bulletin no. 230. Obstet Gynecol. 2021;137(6):e128-e144. doi:10.1097/AOG.0000000000004395